Avanir leaps on NDA submission for migraine drug-device combo
This article was originally published in Scrip
Executive Summary
Shares of Avanir Pharmaceuticals leaped almost 18% in morning trading on 30 January on the news the company had submitted a new drug application (NDA) to FDA for AVP-825, an investigational drug-device combination acute treatment for migraines.